List of Excipients in Branded Drug CELECOXIB

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Blenheim Pharmacal Inc	CELECOXIB	celecoxib	10544-917	CROSCARMELLOSE SODIUM
Blenheim Pharmacal Inc	CELECOXIB	celecoxib	10544-917	GELATIN
Blenheim Pharmacal Inc	CELECOXIB	celecoxib	10544-917	LACTOSE MONOHYDRATE
Blenheim Pharmacal Inc	CELECOXIB	celecoxib	10544-917	MAGNESIUM STEARATE
Blenheim Pharmacal Inc	CELECOXIB	celecoxib	10544-917	POVIDONES

Generic Drugs Containing CELECOXIB

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	celecoxib	0093-7306	D&C RED NO. 28
Teva Pharmaceuticals USA Inc	celecoxib	0093-7306	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	celecoxib	0093-7306	FD&C BLUE NO. 1
Teva Pharmaceuticals USA Inc	celecoxib	0093-7306	FD&C RED NO. 40
Teva Pharmaceuticals USA Inc	celecoxib	0093-7306	FERROSOFERRIC OXIDE

What are the Most Frequently-Used Excipients in CELECOXIB?

# Of NDCs	Excipient
37	ALCOHOL
74	AMMONIA
37	BUTYL ALCOHOL
127	CROSCARMELLOSE SODIUM
55	CROSPOVIDONE

Celecoxib Excipient Strategy and Commercial Opportunities

Last updated: August 6, 2026

Celecoxib is an established, highly genericized selective COX-2 inhibitor with a difficult formulation profile: low aqueous solubility, dose-dependent exposure, and clinically important cardiovascular, gastrointestinal, renal, and sulfonamide-related safety considerations. The strongest commercial opportunities are differentiated oral products that improve dissolution, reduce food-effect variability, simplify dosing, or target pediatric and specialty populations without materially increasing celecoxib exposure.

The reference product, Celebrex, uses conventional hard-gelatin capsules. Its core excipient system is technically replaceable, but generic manufacturers must match dissolution, impurity, stability, and bioequivalence performance. New formulation products may qualify for 505(b)(2) development, while conventional capsules generally compete through ANDA filings and manufacturing economics.

What excipients are used in Celebrex and generic celecoxib capsules?

Celecoxib capsules generally use a conventional powder-fill system containing a diluent, wetting agent, binder, disintegrant, lubricant, and capsule shell materials.

Reference-product excipient profile

The U.S. Celebrex label identifies inactive ingredients that include lactose monohydrate, sodium lauryl sulfate, povidone, croscarmellose sodium, and magnesium stearate. The capsule shell contains gelatin, titanium dioxide, and colorants; printing inks are applied to the shell [1].

Formulation function	Common celecoxib excipient	Technical role
Diluent	Lactose monohydrate	Provides capsule-fill mass and improves powder handling
Wetting agent	Sodium lauryl sulfate	Improves wetting of hydrophobic celecoxib particles
Binder	Povidone	Supports granule or powder cohesion
Disintegrant	Croscarmellose sodium	Promotes capsule-fill breakup after administration
Lubricant	Magnesium stearate	Reduces tooling and capsule-machine friction
Shell	Gelatin, titanium dioxide, colorants	Provides dosage-form integrity and product identification

Generic products may use different excipients, including microcrystalline cellulose, crospovidone, colloidal silicon dioxide, pregelatinized starch, or alternative surfactants. The formulation must remain within the approved product-quality and bioequivalence framework.

Why celecoxib requires excipient engineering

Celecoxib is practically insoluble in water and has high lipophilicity. Its dissolution rate can limit absorption, especially at lower doses and under fasted conditions. Particle size, crystal form, surface area, wetting, granulation, and lubricant concentration can materially affect dissolution.

The drug is commonly treated as a low-solubility, high-permeability compound for formulation purposes. A formulation that improves dissolution can increase exposure, but excessive enhancement may create safety or bioequivalence problems. The commercial target is controlled exposure, not maximum solubilization.

What is the best excipient strategy for celecoxib?

The most defensible strategy is a risk-controlled, immediate-release capsule platform that uses a low level of wetting agent, robust disintegration, and tightly controlled celecoxib particle size.

Recommended development sequence

Priority	Formulation approach	Commercial rationale	Main risk
1	Micronized celecoxib with conventional capsule excipients	Lowest regulatory and manufacturing risk	Limited differentiation
2	Wetting-agent and disintegrant optimization	Improves dissolution without a new dosage form	Potential dissolution overshoot
3	Lipid-based or self-emulsifying system	Addresses hydrophobicity and food-related variability	Stability, capsule compatibility, scale-up
4	Amorphous solid dispersion	Can increase apparent solubility	Physical instability and recrystallization
5	Nanoparticle or nanocrystal formulation	Strong dissolution and lifecycle potential	Process complexity and regulatory burden
6	Oral suspension or sprinkle product	Supports pediatric and swallowing-impaired populations	Dose uniformity and preservative control

A conventional capsule remains the preferred route for an ANDA-oriented product. More complex technologies are better suited to a 505(b)(2) product, particularly where the sponsor seeks a new dosage form, new administration method, or differentiated clinical profile.

Excipient selection principles

A high-value formulation should:

1. Maintain rapid and reproducible dissolution across the labeled dose strengths.
2. Avoid unnecessary surfactant loading.
3. Control powder flow and capsule-fill weight.
4. Minimize capsule-shell interaction and moisture uptake.
5. Support stability under ICH conditions.
6. Avoid excipients that create avoidable allergy, dietary, or pediatric-use barriers.
7. Preserve a clear bioequivalence pathway.

Lactose is commercially convenient but can create a market-access issue for patients with lactose intolerance or for manufacturers pursuing a lactose-free positioning. Gelatin capsules can limit vegetarian, halal, kosher, or certain global-market opportunities. A lactose-free, non-gelatin shell may therefore provide a modest but usable product distinction, although it does not by itself create a strong clinical advantage.

What formulations are protected by celecoxib patents?

Celecoxib’s primary compound patent protection has expired in the United States. The original Celebrex product was developed by G.D. Searle and later commercialized by Pharmacia and Pfizer. The core U.S. patent commonly associated with celecoxib is U.S. Patent No. 5,466,823, covering the pyrazole sulfonamide compound class that includes celecoxib [2].

IP category	Historical position	Current commercial effect
Celecoxib compound patent	U.S. Patent No. 5,466,823	Expired after the original U.S. exclusivity period
Original capsule formulation	Conventional immediate-release capsule	No practical barrier to ordinary generic competition
Method-of-use patents	Inflammatory pain and related indications	Limited leverage where claims overlap approved generic labeling
Later formulation patents	May cover particle size, solid dispersions, salts, combinations, or delivery systems	Relevant only if unexpired, valid, and commercially practiced
Manufacturing patents	May cover crystallization, particle engineering, or process controls	Can create supplier-level barriers but usually does not block ordinary API sourcing

A formulation sponsor should conduct a live patent search before selecting a differentiated platform. The relevant landscape is likely to be concentrated in later formulation, particle-engineering, combination, and delivery-system patents rather than in the basic celecoxib molecule.

How strong is the patent estate for celecoxib?

The base-molecule estate is weak as a barrier to entry because generic celecoxib is widely available. The remaining opportunity is product-specific protection.

A strong formulation patent would need to claim a clinically or commercially meaningful combination of:

• Defined celecoxib particle-size distribution
• Specific crystalline or amorphous form
• Narrow excipient ratios
• Enhanced dissolution under discriminating conditions
• Reduced food-effect variability
• Improved stability
• A distinctive dosage form or administration route

Broad claims covering routine use of common excipients are vulnerable to obviousness and enablement challenges. Narrow claims supported by comparative pharmacokinetic or dissolution data have greater value.

When did celecoxib lose exclusivity?

Celecoxib lost practical U.S. market exclusivity after expiry of its original compound and regulatory protections. The first major generic launches occurred around the 2014-2015 period, after patent litigation and settlement activity involving Pfizer and generic applicants.

Celecoxib has no current U.S. small-molecule exclusivity barrier comparable to an active new chemical entity exclusivity period. Generic manufacturers compete through approved ANDAs, abbreviated labeling, manufacturing scale, supply reliability, and contracting.

Milestone	Commercial significance
1998	FDA approval of Celebrex for acute and chronic pain indications [1]
2014-2015 period	Core U.S. patent protection ended and generic entry expanded
Subsequent years	Multiple ANDA-approved generic products entered the market
Current position	Mature generic NSAID market with limited compound-level IP protection

The original reference product continues to have commercial value through physician familiarity, contracting, brand recognition, and supply relationships. Those factors do not restore exclusivity.

What is the FDA regulatory status of celecoxib?

Celecoxib is FDA-approved as an oral capsule for osteoarthritis, rheumatoid arthritis, acute pain in adults, primary dysmenorrhea, and juvenile rheumatoid arthritis in patients aged two years and older, subject to labeled dosing and safety restrictions [1].

Celecoxib carries the class-level NSAID boxed warning for serious cardiovascular thrombotic events and serious gastrointestinal bleeding, ulceration, and perforation. The label also addresses renal toxicity, hypertension, heart failure, liver effects, hypersensitivity, and sulfonamide-related reactions [1].

Regulatory routes for new celecoxib products

Product concept	Likely FDA route
Same immediate-release capsule and strength	ANDA
New oral suspension with reliance on Celebrex data	505(b)(2)
New sprinkle capsule or modified administration product	505(b)(2)
New fixed-dose combination	505(b)(2) or independent application, depending on formulation and claims
New topical or transdermal product	505(b)(2) or full application, with new local and systemic safety requirements
Complex nanocrystal or amorphous product	Usually 505(b)(2), with formulation-specific CMC and clinical requirements

FDA guidance on ANDA submissions permits excipient differences when the applicant demonstrates pharmaceutical equivalence, bioequivalence, and acceptable inactive-ingredient use [3]. Novel excipient systems can increase the regulatory burden, particularly when exposure, safety, or local tolerability changes.

What commercial opportunities exist for celecoxib excipient innovation?

The strongest opportunities are in differentiated oral products rather than standard generic capsules.

1. Fasted-state dissolution products

Celecoxib exposure can vary with food. A formulation that delivers more consistent dissolution under fasted conditions could target patients who cannot reliably coordinate dosing with meals.

Commercial value depends on demonstrating a meaningful pharmacokinetic advantage. A faster dissolution profile alone may not support premium pricing unless it translates into faster onset, lower variability, or an approved administration benefit.

2. Pediatric oral suspension

Celecoxib has pediatric labeling for juvenile rheumatoid arthritis, but capsules are not ideal for young children or patients unable to swallow solid dosage forms. A stable suspension could address:

• Weight-based dosing
• Dose flexibility
• Pediatric administration
• Caregiver convenience
• Hospital and specialty-pharmacy use

Key excipient issues include suspending agents, wetting agents, buffers, sweeteners, preservatives, flavor systems, and dose-uniformity controls. The product must avoid sedimentation that produces clinically meaningful dose variation.

3. Sprinkle capsule or multiparticulate product

A sprinkle formulation could improve administration for pediatric patients and adults with dysphagia. The multiparticulate system would need to maintain dose uniformity, avoid premature release in the mouth, and remain compatible with soft food or liquid vehicles.

This product has greater differentiation than a standard capsule but requires administration-method labeling, palatability testing, and potentially a 505(b)(2) strategy.

4. Lactose-free and non-gelatin products

A lactose-free capsule can reach patients who avoid lactose-containing products. A vegetarian or hydroxypropyl methylcellulose capsule can expand institutional and international procurement options.

These changes are commercially useful but generally weak as standalone IP. Their value increases when combined with improved dissolution, a cleaner excipient profile, or a specialty-market distribution strategy.

5. Lipid-based delivery

Self-emulsifying drug-delivery systems can improve wetting and apparent solubilization of celecoxib. Potential excipients include medium-chain triglycerides, nonionic surfactants, and cosolvents.

The principal development risks are:

• Precipitation after dilution in gastrointestinal fluid
• Capsule-shell leakage or brittleness
• Oxidative degradation
• Food-dependent performance
• High excipient load
• Manufacturing complexity

Lipid systems are more commercially attractive when they solve a defined problem, such as fasted-state variability or lower-dose performance.

6. Amorphous solid dispersion

Polymer-based amorphous dispersions can increase apparent solubility and delay recrystallization. Suitable polymers may include povidone, copovidone, hydroxypropyl cellulose, or hypromellose-based systems.

The key technical barrier is physical stability. Celecoxib can recrystallize during storage or after contact with gastrointestinal fluid. A successful product requires solid-state characterization, moisture control, accelerated stability data, and dissolution testing capable of detecting performance loss.

7. Combination products

Celecoxib may be combined with agents targeting complementary pain mechanisms, such as acetaminophen. Combination products can improve convenience but create dose-ratio, safety, labeling, and patent risks.

The cardiovascular and gastrointestinal risks of celecoxib remain relevant in a combination product. A combination does not automatically create a safer NSAID profile.

What generic entry risks exist for a new celecoxib product?

The main risk is that a technically improved product will fail to justify premium economics in a mature generic market.

Manufacturing and CMC barriers

Important manufacturing controls include:

• API particle-size distribution
• Polymorphic form
• Blend uniformity
• Lubrication time
• Granule moisture
• Capsule-fill weight
• Dissolution across pH conditions
• Impurity and degradation-product control
• Stability of the capsule shell

Celecoxib suppliers with validated micronization, crystallization, and analytical controls can have an advantage over low-cost API sources. The manufacturing barrier is real but usually manageable for standard capsules.

Bioequivalence risk

A more soluble formulation can generate higher peak concentration or area under the curve. This may create failure risk even when dissolution appears superior. The product should be designed against the reference product’s in vivo profile, not against the fastest possible dissolution.

For complex formulations, conventional single-dose fasting and fed studies may not fully characterize performance. The sponsor may need comparative pharmacokinetic studies, fed-state testing, food-effect analysis, and additional clinical evidence.

Safety and excipient risk

Celecoxib is a sulfonamide-containing drug. The product label warns about hypersensitivity reactions, including serious skin reactions and anaphylaxis [1]. Excipient choices should avoid adding unnecessary allergen, intolerance, or pediatric-use concerns.

Propylene glycol, ethanol, certain preservatives, and high surfactant loads may create avoidable restrictions in pediatric or institutional markets.

What is the Orange Book status of celecoxib?

Celebrex is listed in FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The product is the reference listed drug for generic celecoxib capsule applications [4].

The central Orange Book implications are:

• Generic applicants reference Celebrex through ANDA pathways.
• Historical listed patents associated with the original product no longer create a practical compound-level entry barrier.
• Paragraph IV certifications were relevant during the original generic-entry period.
• A new unexpired formulation patent could create a separate listing and litigation pathway if it meets FDA listing requirements.

What were the Paragraph IV issues?

Generic applicants seeking approval before relevant patent expiry could submit Paragraph IV certifications asserting that listed patents were invalid, unenforceable, or not infringed. Such certifications could trigger patent litigation under the Hatch-Waxman framework.

Celecoxib generic entry followed this standard pattern. The commercial effect of those disputes has largely passed because the core patent estate expired and multiple generic products entered the market. Any current dispute would likely involve a later formulation or use patent rather than the original celecoxib molecule.

Which companies compete in the celecoxib market?

The market includes Pfizer’s Celebrex brand and numerous generic manufacturers and distributors. Generic competition is typically divided among large multisource manufacturers, specialty generic companies, contract manufacturers, and regional suppliers.

Competitive differentiation is based on:

• Wholesale acquisition cost
• Contract pricing
• Supply continuity
• FDA manufacturing history
• API security
• Capsule-strength breadth
• Hospital and government tenders
• Specialty formulations
• International registration coverage

A new conventional capsule is unlikely to obtain durable premium pricing without a protected formulation or a strong distribution position. A pediatric suspension, sprinkle product, or clinically differentiated formulation has greater potential for specialty-market economics.

How does celecoxib compare with other NSAID formulation opportunities?

Attribute	Celecoxib	Ibuprofen	Naproxen
Solubility challenge	High	Moderate	Moderate to high
COX selectivity	Preferential COX-2 inhibitor	Nonselective	Nonselective
Formulation opportunity	Strong for dissolution and food-effect control	Strong for rapid onset and liquid products	Strong for extended release and liquid products
Key safety concern	Cardiovascular, renal, GI, hypersensitivity	GI, renal, cardiovascular	GI, renal, cardiovascular
Premium product potential	Specialty oral and pediatric formats	OTC convenience and rapid-onset formats	Long-acting and combination products
IP landscape	Base molecule mature; formulation IP may matter	Highly mature	Highly mature

Celecoxib is more attractive than many older NSAIDs for specialized formulation work because its poor aqueous solubility creates a clear technical problem. The same characteristic also creates greater bioequivalence and stability risk.

What licensing opportunities exist for celecoxib technology?

The most valuable licensing targets are formulation platforms rather than the celecoxib molecule itself.

Potential deal structures include:

• Exclusive regional rights to a 505(b)(2) oral suspension
• Licensing of a nanocrystal or amorphous-dispersion platform
• Supply and development agreements with micronized API manufacturers
• Co-development of pediatric or dysphagia-friendly products
• Manufacturing licenses for lipid-based capsule technology
• Geographic rights for emerging-market registration and supply

The original commercial rights originated with Searle and transferred through Pharmacia to Pfizer. Current opportunity is more likely to involve platform owners, generic manufacturers, specialty-pharma companies, and regional licensees than the original molecule owner.

What generic launch scenarios are most likely for celecoxib?

Standard generic capsule

This is the lowest-risk scenario but also the least differentiated. Success depends on cost, reliable supply, and contracting. Expected pricing pressure is high.

Specialty generic

A lactose-free capsule, non-gelatin capsule, or broader strength portfolio can create modest differentiation. The product remains exposed to generic substitution and limited pricing power.

505(b)(2) suspension or sprinkle product

This scenario has a higher development burden but can target pediatric, geriatric, hospital, and specialty-pharmacy channels. It has a better chance of sustaining premium economics if the administration benefit is reflected in labeling.

Complex formulation

A lipid, nanocrystal, or amorphous-dispersion product can support formulation patents and a differentiated regulatory strategy. Its value depends on demonstrated clinical or pharmacokinetic improvement and manufacturing scalability.

Key Takeaways

• Celecoxib’s main formulation problem is poor aqueous solubility and dissolution-limited absorption.
• The reference capsule uses lactose, sodium lauryl sulfate, povidone, croscarmellose sodium, magnesium stearate, and gelatin-based shell materials.
• Standard generic capsules face little compound-level patent protection and intense price competition.
• The strongest opportunities are pediatric suspensions, sprinkle products, fasted-state formulations, and controlled-solubility systems.
• Micronization, surfactant selection, disintegration, polymorph control, and dissolution testing are the central CMC issues.
• New formulation products may use a 505(b)(2) pathway, while conventional capsules generally use ANDAs.
• Formulation patents must claim more than routine excipient substitution to create durable commercial protection.
• A premium product must demonstrate a meaningful administration, pharmacokinetic, stability, or patient-access advantage.

FAQs About Celecoxib Excipient and Commercial Strategy

Can celecoxib be formulated without lactose?

Yes. Lactose can be replaced with microcrystalline cellulose, mannitol, starch-based fillers, or other suitable diluents. The replacement must preserve blend uniformity, capsule-fill performance, dissolution, stability, and bioequivalence.

Is sodium lauryl sulfate necessary in celecoxib capsules?

No. It is commonly used to improve wetting, but alternative surfactants or particle-engineering approaches may be viable. Removing it can change dissolution and exposure, so the formulation requires comparative performance testing.

Is a celecoxib oral suspension commercially attractive?

Yes, particularly for pediatric and dysphagia populations. The opportunity is strongest where the product provides reliable weight-based dosing, acceptable taste, physical stability, and convenient administration.

Can a new celecoxib formulation receive a new patent?

Potentially. Patentability is stronger for a defined formulation with unexpected dissolution, stability, pharmacokinetic, or clinical results than for routine substitution of common excipients.

Does celecoxib have biosimilar risk?

No. Celecoxib is a synthetic small-molecule drug, not a biologic. Its relevant competitive risk comes from generic ANDA products and differentiated small-molecule formulations, not biosimilars.

References

1. U.S. Food and Drug Administration. (2023). Celebrex (celecoxib) prescribing information.
2. U.S. Patent No. 5,466,823. (1995). Pyrazole compounds useful as anti-inflammatory agents.
3. U.S. Food and Drug Administration. (2019). Inactive ingredient database and guidance for industry: ANDAs for certain highly purified synthetic drug substances.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations, Orange Book.